Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Schizophrenia is a disabling and often chronic disorder that may require long-term treatment. This protocol is an extension study of a randomised study comparing the safety of Sertindole versus Risperidone. Patients who were randomised to Sertindole and who completed the previous study have the possibility to receive continued Sertindole treatment in this open one-arm study. Sertindole is generally well tolerated and is approved in the EU, but not yet marketed in France. The follow-up of the patients will be similar to that in the previous study and requires quarterly visits. Patient management reflects routine clinical practice in accordance with the Sertindole label. Any severe safety issue is reported to the company.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participation in the previous SCoP study, 99824
Still fulfils the EU SPC requirements for Sertindole
You may not be if
Withdrawn before the end of the SCoP study, 99824
Become homeless
Participation in another clinical trial at the same time
Unlikely to comply with the clinical study protocol or is unsuitable for any reason
Clareo Health | Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia
